Juvenile Macular Degeneration Drug Pipeline Analysis 2015

Global Markets Direct’s, ‘Juvenile Macular Degeneration (Stargardt Disease) – Pipeline Review, H1 2015′, provides an overview of the Juvenile Macular Degeneration (Stargardt Disease)’s therapeutic pipeline.

Juvenile Macular Degeneration is the inherited eye disease. It can affect children and young adult. Juvenile Macular Degeneration is the breakdown of the eye’s macula. People with Juvenile Macular Degeneration lose part or all of their central vision. They may have problems in identifying color, dislike bright light in the early stages. It is also possible to develop macular degeneration in only one eye.

This report provides comprehensive information on the therapeutic development for Juvenile Macular Degeneration (Stargardt Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and special features on late-stage and discontinued projects.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Complete Report is Available at http://www.rnrmarketresearch.com/juvenile-macular-degeneration-stargardt-disease-pipeline-review-h1-2015-market-report.html  .

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Scope:

• The report provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Stargardt Disease).
• The report reviews key pipeline products under drug profile section which includes product description, MoA and R&D brief, licensing and collaboration details & other developmental activities.
• The report reviews key players involved in the therapeutics development for Juvenile Macular Degeneration (Stargardt Disease) and enlists all their major and minor projects.
• The report summarizes all the dormant and discontinued pipeline projects.
• A review of the Juvenile Macular Degeneration (Stargardt Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages.

Order a Purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=269603 . (This is a premium report priced at US$2000 for a single user License.)

RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.